Olmesartan Medoxomil E Amlodipina Accord (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil E Amlodipina Accord, is an Angiotensin II receptor blocker (ARB) presented as a oral tablet for hypertension management in adults. It helps lower blood pressure and reduces cardiovascular risk.

GNH USA supplies Olmesartan Medoxomil E Amlodipina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil E Amlodipina Accord combines an ARB with a calcium‑channel blocker to address the renin‑angiotensin system and vascular tone pathways. - Hypertension: Improves blood pressure control when monotherapy is insufficient. - Hypertension with isolated systolic hypertension: Provides additional systolic pressure reduction. - Hypertension in patients with metabolic syndrome: Offers effective BP lowering with a favorable metabolic profile.

Adverse reactions may occur with any antihypertensive regimen.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing - Fatigue - Nasal congestion

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Hepatic enzyme elevation - Acute kidney injury - Myocardial infarction in rare cases - Severe allergic reactions (anaphylaxis)

Use of this combination requires careful clinical assessment and monitoring. - Blood pressure monitoring: Check BP regularly to avoid excessive lowering. - Renal function: Assess baseline kidney function and adjust if needed. - Hepatic function: Monitor liver enzymes in patients with liver disease. - Electrolyte balance: Observe potassium and sodium levels, especially if used with diuretics. - Pregnancy: Contra‑indicated in the second and ​  ​  ​  ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ‑  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Breastfeeding: Weigh benefits against potential infant exposure. - Drug interactions: Review concomitant antihypertensives and potassium‑sparing agents. - Store at   -   -  

The